Celgene International Sárl
104 articles about Celgene International Sárl
-
Celgene International Sárl Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase II RADIANCE Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS
9/16/2016
-
Celgene International Sárl Release: Oral Presentation Evaluating Pooled Data On OTEZLA (apremilast) For Long-Term Improvements In Enthesitis And Dactylitis To Be Presented At EULAR
6/10/2015
-
Celgene International Sárl Release: ABRAXANE Approved By European Commission For First-Line Treatment Of Patients With Non-Small Cell Lung Cancer
3/2/2015
-
Celgene International Sárl Release: ABRAXANE Now Reimbursed In Italy As A First-Line Treatment Of Adult Patients With Metastatic Pancreatic Cancer
2/24/2015
-
Celgene International Sárl Release: REVLIMID (Lenalidomide) Approved By European Commission (EC) For The Treatment Of Adult Patients With Previously Untreated Multiple Myeloma Who Are Not Eligible For Transplant
2/23/2015
-
Celgene International Sárl Release: Oral OTEZLA® (Apremilast) Approved By The European Commission For The Treatment Of Both Patients With Psoriasis And Psoriatic Arthritis
1/16/2015
-
Celgene International Sárl Release: Oral OTEZLA® (Apremilast) Data Presented At EADV Show Improved Measures Of Health-Related Quality Of Life And Work Productivity In Patients With Moderate To Severe Plaque Psoriasis
10/10/2014
-
Celgene International Sárl Release: New Analyses Of Oral OTEZLA® (Apremilast) Presented At EADV Show Efficacy In Difficult-To-Treat Areas Of Moderate To Severe Plaque Psoriasis
10/10/2014
-
Celgene International Sárl To Present Long-Term Efficacy And Safety Data On Oral OTEZLA® (Apremilast) In Plaque Psoriasis And Psoriatic Arthritis At European Academy Of Dermatology And Venereology Congress
10/7/2014
-
Celgene International Sárl Release: Retrospective Analysis Of Overall Survival Adjusting For Patient Crossover In Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Presented At EHA
6/16/2014
-
Celgene International Sárl Release: Results From Phase III Study (AML-001) Of VIDAZA® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At European Hematology Association
6/16/2014
-
Celgene International Sárl Release: First-Of-Its-Kind Multinational Survey Confirms Psoriasis And Psoriatic Arthritis Patients Are Frequently Undertreated Or Not Treated At All
3/20/2014
-
Celgene International Sárl Release: ABRAXANE® Plus Gemcitabine Receives European Marketing Authorization For First-Line Treatment Of Patients With Metastatic Pancreatic Cancer
1/7/2014
-
Celgene International Sárl Release: Studies Evaluating REVLIMID® (Lenalidomide) In Lymphoma Presented At American Society of Hematology
12/11/2013
-
Celgene International Sárl Release: Two Studies Highlight Retrospective Analyses Of Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Patients Presented At American Society of Hematology
12/10/2013
-
Celgene International Sárl Release: REVLIMID® (Lenalidomide)-Treated Patients With Deletion-5q MDS Who Achieve Transfusion-Independence Of At Least 26 Weeks And AML-Free Survival Associated With Cytogenetic Response
12/10/2013
-
First Analysis Of Extended Dosing With Celgene International Sárl Epigenetic Agent CC-486 In Patients With Higher-Risk Myelodysplastic Syndromes Presented At American Society of Hematology
12/9/2013
-
Celgene International Sárl Receives Positive CHMP Opinion For ABRAXANE® In Combination With Gemcitabine As Treatment For Patients With Metastatic Pancreatic Cancer
11/22/2013
-
Celgene International Sárl Release: Initial Phase 3 Results of the FIRST® Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at American Socie
11/7/2013
-
Celgene International Sárl Release: ABRAXANE® Phase III Study of Patients With Metastatic Pancreatic Cancer Published in The New England Journal of Medicine
10/17/2013